SEARCH

SEARCH BY CITATION

References

  • 1
    Bennett WM, DeMattos A, Meyer MM et al. Chronic cyclosporine nephropathy: The Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 10891100.
  • 2
    Burdmann EA, Andoh TF, Yu L et al. Cyclosporine nephrotoxicity. Semin Nephrol 2003; 23: 465476.
  • 3
    Luke RG. Mechanism of cyclosporine-induced hypertension. Am J Hypertens 1991; 4: 468471.
  • 4
    Curtis JJ. Hypertension following kidney transplantation. Am J Kidney Dis 1994; 23: 471475.
  • 5
    Kobashigawa JA, Kasiske BL. Hyperlipidemia in solid organ transplantation. Transplantation 1997; 63: 331338.
  • 6
    Webster AC, Woodroffe RC, Taylor RS et al. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. BMJ 2005; 331: 810.
  • 7
    Howard RJ, Patton PR, Reed AI et al. The changing causes of graft loss and death after kidney transplantation. Transplantation 2002; 73: 19231928.
  • 8
    Ojo AO, Hanson JA, Wolfe RA et al. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307313.
  • 9
    Matas AJ, Humar A, Gillingham KJ et al. Five preventable causes of kidney graft loss in the 1990s: A single-center analysis. Kidney Int 2002; 62: 704714.
  • 10
    Kasiske BL, Chakkera HA, Louis TA et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 19101917.
  • 11
    Vincenti F, Kirkman R, Light S et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161165.
  • 12
    Nashan B, Light S, Hardie IR et al. Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group. Transplantation 1999; 67: 110115.
  • 13
    Ekberg H, Backman L, Tufveson G et al. Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis. Transplant Int 2000; 13: 151159.
  • 14
    European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. European Mycophenolate Mofetil Cooperative Study Group. Lancet 1995; 345: 13211325.
  • 15
    Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225232.
  • 16
    Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61: 10291037.
  • 17
    Weir MR, Anderson L, Fink JC et al. A novel approach to the treatment of chronic allograft nephropathy. Transplantation 1997; 64: 17061710.
  • 18
    Ducloux D, Fournier V, Bresson-Vautrin C et al. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: A preliminary report. Transplantation 1998; 65: 15041506.
  • 19
    Hueso M, Bover J, Seron D et al. Low-dose cyclosporine and mycophenolate mofetil in renal allograft recipients with suboptimal renal function. Transplantation 1998; 66: 17271731.
  • 20
    Schrama YC, Joles JA, Van Tol A et al. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients. Transplantation 2000; 69: 376383.
  • 21
    Houde I, Isenring P, Boucher D et al. Mycophenolate mofetil, an alternative to cyclosporine A for long-term immunosuppression in kidney transplantation? Transplantation 2000; 70: 12511253.
  • 22
    Tran HT, Acharya MK, McKay DB et al. Avoidance of cyclosporine in renal transplantation: Effects of daclizumab, mycophenolate mofetil, and steroids. J Am Soc Nephrol 2000; 11: 19031909.
  • 23
    Vincenti F, Ramos E, Brattstrom C et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 12821287.
  • 24
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 3141.
  • 25
    Solez K, Benediktsson H, Cavallo T et al. Report of the Third Banff Conference on Allograft Pathology (July 20-24, 1995) on classification and lesion scoring in renal allograft pathology. Transplant Proc 1996; 28: 441444.
  • 26
    Abramowicz D, Manas D, Lao M et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study. Transplantation 2002; 74: 17251734.
  • 27
    Schnuelle P, Van Der Heide JH, Tegzess A et al. Open randomized trial comparing early withdrawal of either cyclosporine or mycophenolate mofetil in stable renal transplant recipients initially treated with a triple drug regimen. J Am Soc Nephrol 2002; 13: 536543.
  • 28
    Smak Gregoor PJ, De Sevaux RG, Ligtenberg G et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: A randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 13651373.